This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-09. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Gender-affirming care == Various options are available for transgender people to pursue physical transition. There have been options for transitioning for transgender individuals since 1917. Gender-affirming care helps people to change their physical appearance and/or sex characteristics to accord with their gender identity; it includes gender-affirming hormone therapy and gender-affirming surgery. While many transgender people do elect to transition physically, every transgender person has different needs and, as such, there is no required transition plan. Preventive health care is a crucial part of transitioning and a primary care physician is recommended for transgender people who are transitioning.
== Research == Morgan is a public research university that engages in active research with several national and international organizations and agencies including the National Science Foundation, National Institutes of Health, and United States Department of Defense. The research centers and programs are supported by and operated out of the various schools and institutions of the university.
== History == Clocinnamox (CCAM) was first described in the scientific literature by 1992. MCCAM was first described by 1995. It was developed by researchers at the National Institute on Drug Abuse (NIDA) of the United States National Institutes of Health (NIH). The drug was of interest in the possible treatment of opioid dependence. However, it was never marketed. Methocinnamox (MCAM), a close analogue of MCCAM, was first described in 2000. MCAM was under development for the treatment of opioid dependence and opioid overdose by 2020.
Sources: en.wikipedia.org
In 2017, Forever 21 produced a clothing line in partnership with Taco Bell, featuring branded T-shirts and sweatshirts, as well as bodysuits made to look like Border Sauce packets. In November 2019, Taco Bell announced Taco Bell's Taco Shop, an online store with Taco Bell branded merchandise including hoodies and tees, holiday ornaments, inflatable sauce packets, and wedding-related items.
=== Stroke === The role of IGF-1 in supporting recovery from stroke, which is a condition of vascular origin, is reported. A study in 34 stroke patients reported that patients with higher plasma concentration of cGP made better recovery within 3 months than those with lower cGP levels. Further, patients with higher cGP levels also showed lesser neurological deficits.
Human Growth Hormone Fragment 176–191 (hGH frag 176–191) is a peptide fragment of human growth hormone. It has erroneously been presented as a lipolytic peptide fragment based on extrapolations of clinical data pertaining to AOD9604, a modified form of hGH frag 176–191. In contrast to AOD9604, hGH frag 176–191 has not been studied in humans.
Committee on Natural Resources Subcommittee on Federal Lands Subcommittee on Water, Wildlife and Fisheries Committee on Oversight and Government Reform Subcommittee on Delivering on Government Efficiency (Ranking Member)
Sources: en.wikipedia.org
The structure of tRNA can be decomposed into its primary structure, its secondary structure (usually visualized as the cloverleaf structure), and its tertiary structure (all tRNAs have a similar L-shaped 3D structure that allows them to fit into the P and A sites of the ribosome). The cloverleaf structure becomes the 3D L-shaped structure through coaxial stacking of the helices, which is a common RNA tertiary structure motif. The lengths of each arm, as well as the loop 'diameter', in a tRNA molecule vary from species to species. The tRNA structure consists of the following:
Although an adult bear is quite capable of killing a human, American black bears typically avoid confronting humans. Unlike grizzly bears, which became a subject of fearsome legend among the European settlers of North America, black bears were rarely considered overly dangerous, even though they lived in areas where the pioneers had settled. American black bears rarely attack when confronted by humans and usually only make mock charges, emit blowing noises and swat the ground with their forepaws. The number of attacks on humans is higher than those by brown bears in North America, but this is largely because black bears considerably outnumber brown bears. Compared to brown bear attacks, aggressive encounters with black bears rarely lead to serious injury. Most attacks tend to be motivated by hunger rather than territoriality and thus victims have a higher probability of surviving by fighting back rather than submitting. Unlike female brown bears, female American black bears are not as protective of their cubs and rarely attack humans in the vicinity of the cubs. However, occasionally such attacks do occur. The worst recorded attack occurred in May 1978, in which a bear killed three teenagers fishing in Algonquin Provincial Park in Ontario. Another exceptional attack occurred in August 1997 in Liard River Hot Springs Provincial Park in British Columbia, when an emaciated bear attacked a mother and child, killing the mother and a man who intervened. The bear was shot while mauling a fourth victim.
=== In mango === In mangoes, PPO catalyzed enzymatic browning is mainly caused by sap burn which leads to skin browning. Catechol oxidase–type PPO is located in the chloroplasts of mango skin cells and its phenolic substrates in the vacuoles. Sap burn is therefore the initiating event of PPO in mango skin, as it breaks down cell compartments. PPO is located in mango skin, sap and pulp, with highest activity levels in skin.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.